EXHIBIT 10.33
IMMUNOGEN, INC. HAS OMITTED FROM THIS EXHIBIT 10.33 PORTIONS OF THE AGREEMENT
FOR WHICH IMMUNOGEN, INC. HAS REQUESTED CONFIDENTIAL TREATMENT FROM THE
SECURITIES AND EXCHANGE COMMISSION. THE PORTIONS OF THE AGREEMENT FOR
WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED ARE MARKED WITH AN
ASTERISK AND SUCH CONFIDENTIAL PORTIONS HAVE BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION.
LICENSE AGREEMENT
THIS AGREEMENT effective this July 31, 1997 (the "Effective Date"), between Apoptosis Technology, Inc., a
corporation organized and existing under the laws of the Commonwealth of Massachusetts having a place of
business at 148 Sidney Street, Cambridge, Massachusetts, USA (hereinafter "ATI"), BioChem Pharma Inc., a
corporation organized and existing under the laws of Canada having a place of business at 275 Armand-Frappier
Boulevard, Laval, Quebec, Canada, Tanaud Holdings (Barbados) Ltd., a corporation organized and existing
under the laws of Barbados having a place of business at Chancery Chambers, Chancery House, High Street,
Bridgetown, Barbados, and Tanaud L.L.C., a limited liability company organized and existing under the laws of
the State of Delaware having a place of business at Bush Hill, Bay Street, Bridgetown, Barbados. For the
purposes of this Agreement, BioChem Pharma Inc., Tanaud Holdings (Barbados) Ltd. and Tanaud L.L.C. shall
be referred to collectively as "BioChem".
WITNESSETH:
WHEREAS ATI and an Affiliate of BioChem have executed a Research Collaboration Agreement of even date
in which they have agreed to apply their technology and expertise to discover and develop additional screens and
to discover, develop, manufacture and sell human therapeutic products for the prevention or treatment of human
diseases (the "Research Collaboration Agreement");
WHEREAS BioChem and ATI wish to grant licenses to one another to assist in the carrying out of the Research
Program and the Drug Discovery and Development Program and the development and commercializat